Dr. Gill is Co-Leader of the Translational & Clinical Sciences Program at USC Norris. Gill’s research focuses on the identification of novel cancer and cancer blood vessel targets, and validation of the targets in various model systems including genetic mouse models. Following the target identification and validation, his group generates therapeutic proteins and antibodies. He is currently the Principal Investigator and co-leader of multiple NIH-funded grants (P50, P30), and the Principal Investigator on a DOD grant on AXL-targeting antibody-drug conjugate as a novel therapy for triple negative breast cancer.